 Home > Active Ingredient News > Drugs Articles > FDA approves Novartis' targeted radioligand therapy Pluvicto for prostate cancer

FDA approves Novartis' targeted radioligand therapy Pluvicto for prostate cancer

 Last Update: 2022-04-29
 Source: Internet
 Author: User

Tags

surfactant replacement therapy

fragment based drug discovery

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Novartis announced today that the U.
S.
Food and Drug Administration (FDA) has approved the company’s targeted radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan, formerly known as 177Lu-PSMA-617) for the treatment of prostate-specific membrane antigen (PSMA).
) in patients with metastatic castration-resistant prostate cancer (mCRPC)
.

They had been treated with taxane-based chemotherapy and androgen receptor signaling pathway inhibitors

In recent years, radiopharmaceuticals have become an important direction in the field of precision tumor therapy
.

Novartis' Pluvicto links small-molecule compounds that bind PSMA to radioisotopes

▲Introduction to Pluvicto (177Lu-PSMA-617) therapy (Image source: Novartis official website)

This approval is based on positive results from a pivotal Phase 3 clinical trial
.

Trial results showed that the addition of Pluvicto reduced the risk of death by 38% compared to standard treatment, and Pluvicto also significantly reduced the risk of radiological disease progression or death

References:

[1] Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.